XML 84 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Marketable Securities
 12 Months Ended
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities Marketable Securities

Immunomedics considers all of its current investments to be available-for-sale. Marketable securities are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive (loss) income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net loss and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in interest and other income (net). As of December 31, 2019, and 2018, the carrying value of our current investments due after one year or more are $4.5 million and $4.9 million, respectively.

The following table summarizes the marketable securities held as of December 31, 2019 and 2018 (in thousands):
 December 31, 2019
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized (Loss)
 
Fair Value
U.S. Government Sponsored Agencies
$
4,941

 
$
—

 
$
(391
)
 
$
4,550



 December 31, 2018
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized (Loss)
 
Fair Value
U.S. Government Sponsored Agencies
$
4,941

 
$
—

 
$
—

 
$
4,941